Vytorin Derivative Suit Settlement Wins Initial Nod

Law360, New York (January 10, 2012, 6:59 PM EST) -- A New Jersey federal judge on Tuesday preliminarily approved a settlement in a shareholder derivative suit accusing former Schering-Plough Corp. directors of hiding the lackluster performance of the Merck & Co. Inc. unit's anti-cholesterol drug Vytorin for nearly two years after a clinical trial.

U.S. District Judge Dennis M. Cavanaugh signed off on the terms of the settlement, which include requirements that Merck Research Laboratories must divulge any such delays in reporting the results of clinical trials to the research committee of Merck’s board of directors,...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

CAIN v. HASSAN et al


Case Number

2:08-cv-01022

Court

New Jersey

Nature of Suit

Securities/Commodities

Judge

Dennis M. Cavanaugh

Date Filed

February 25, 2008

Law Firms

Companies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.